Thermo Fisher Scientific Inc. Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $211.43, for a total transaction of $211,430.00.
Following the completion of the sale, the director now owns 11,660 shares of the company’s stock, valued at $2,465,273.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Thermo Fisher Scientific Inc. (TMO) opened at $208.58 on Thursday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. Thermo Fisher Scientific Inc. has a 52 week low of $151.74 and a 52 week high of $226.44. The stock has a market cap of $83,640.00, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 1.57 and a beta of 1.11.
Thermo Fisher Scientific last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion.
During the same period in the previous year, the firm earned $2.41 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 22.1% on a year-over-year basis. sell-side analysts predict that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend is Wednesday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 9.84%.
Several hedge funds and other institutional investors have recently bought and sold shares of TMO. Ark Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 2.8% during the second quarter. Ark Investment Management LLC now owns 18,005 shares of the medical research company’s stock worth $3,141,000 after purchasing an additional 488 shares in the last quarter.
Ropes Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares in the last quarter. Veritable L.P. lifted its position in shares of Thermo Fisher Scientific by 32.2% during the second quarter. Veritable L.P. now owns 19,152 shares of the medical research company’s stock worth $3,341,000 after purchasing an additional 4,668 shares in the last quarter. Bank of Hawaii lifted its position in shares of Thermo Fisher Scientific by 0.9% during the second quarter.
Bank of Hawaii now owns 18,105 shares of the medical research company’s stock worth $3,159,000 after purchasing an additional 163 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 1.2% during the second quarter. Voya Investment Management LLC now owns 148,740 shares of the medical research company’s stock worth $25,951,000 after purchasing an additional 1,739 shares in the last quarter. 86.54% of the stock is currently owned by institutional investors and hedge funds.